solid need progress toward adjust
model follow earn follow-up call compani
chang lead us modestli reduc sale estim vivitrol
rais aristada given product strong perform
quarter meaning increas expens assumpt given
invest compani need make expand schizophrenia
franchis ahead potenti approv along
near-term bump support invest pipelin
especi maintain under-perform rate tp
compani outlook compani present full
data medic meet could allow us
street better appreci commerci potenti product
topic busi develop also came sever time today
confer call previou convers compani mention
could interest acquir asset natur focu
possibl oncolog depend progress think
would make sens especi provid compani attract mid-
late stage asset fill gap pipelin behind ahead
early-stag asset seem enthusiast intern
maintain under-perform price tp base
blend dcf rel valuat use
wacc along perpetu growth rate dcf valuat
appli multipl estim forward revenu deriv
rel valuat ep move
main risk view stock
surprisingli strong commerci execut key market product
vivitrol aristada unexpectedli posit news pipelin
especi
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
plc global biopharmaceut compani research
develop commerci partner
pharmaceut product design address central
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat base vivitrol
schizophrenia franchis gener peak combin sale
blue sky valuat base dcf driven
wacc along termin growth rate thereaft
grey sky valuat base vivitrol gener
peak sale sale grey sky
valuat base dcf driven wacc along
 close
us million unless otherwis state
sale
share
figur guidanc compar cs consensu estim
incom tax effect relat reconcil item
us million unless otherwis state
us thousand unless otherwis state
us thousand unless otherwis state
research develop revenu
amort acquir intang asset
chang fair valu conting consider
average number common share out non-gaap
 sale
sg sale
compani mention price
